Study of the erythropoiesis activity of nano-encapsulated forms of erythropoietin


 

 

New articles in this journal are licensed under a Creative Commons Attribution 3.0 United States License. 

 

 

This journal is published by theUniversity Library System of the University of Pittsburgh as part  

of its D-Scribe Digital Publishing Program and is cosponsored by the University of Pittsburgh Press. 

 

 

 

 

 

 

 
 

 

 

 

 

Study of the erythropoiesis 

activity of nano-encapsulated 

forms of erythropoietin 

 

Zhanagul Khasenbekova1, 

Alexandr Gulayev1, Elena 

Nechayeva2, Talgat Nurgozhin1, 

Zhaxybay Zhumadilov1 

 
1Center for Life Sciences, Nazarbayev 
University 
2The State Research Center of Virology 
and Biotechnology VECTOR, Novosibirsk, 
Russia 

 

Vol. 2, Suppl. (2013)   |   ISSN 2166-7403 (online)  

DOI 10.5195/cajgh.2013.110  |   http://cajgh.pitt.edu 

http://www.library.pitt.edu/
http://www.pitt.edu/
http://www.library.pitt.edu/articles/digpubtype/index.html
http://www.upress.pitt.edu/upressIndex.aspx
http://creativecommons.org/licenses/by/3.0/us/


 

 

KHASENBEKOVA 

 

 

This work is licensed under a Creative Commons Attribution 3.0 United States License. 

 

This journal is published by theUniversity Library System of the University of Pittsburgh as part  

of its D-Scribe Digital Publishing Program and is cosponsored by the University of Pittsburgh Press. 

 

Central Asian Journal of Global Health 

Volume 2, Suppl. (2013) |  ISSN 2166-7403 (online) | DOI 10.5195/cajgh.2013.110 | http://cajgh.pitt.edu 

 

 

Abstract 

Introduction: The recombinant human erythropoietin (rhEPO) is used in the treatment of anemia. In order to improve its 

pharmacokinetic properties, nanoparticles of biodegradable polymers of natural or synthetic origin were used. The aim of this 

study was to investigate the effect of new nano-encapsulated forms of recombinant human erythropoietin for oral use on the 

erythropoiesis in the cyclophosphamide immunosuppression model. 

 

Material and methods: The CHOpE immortalized cells culture (a primary producer of rhEPO "Vector" in Russia) was used. 

The following biodegradable polymers were chosen: 0.05% and 0.005% carbopol, 0.05% and 0.005% kollidon, and 0.05% and 

0.005% pectin. Immunosuppression was obtained by a single dose of i.p. injection of cyclophosphamide (250 mg/kg) in white 

mice (18-20 g). During the next 5 days, the nano-encapsulated erythropoietin (100 ED/mouse) was administered orally to each 

mouse. After 5 and 10 days, the cell count of the number of blood reticulocytes and the myelogram of bone marrow were 

performed. The control group of mice received injections of Eprex. 

 

Results: On the 5th day of the experiment, the highest level of reticulocyte was observed in the samples of erythropoietin with 

kollidon (0.05%) and pectin (0.005%) nanoparticles. On the 10th day, the highest activity was observed in the samples of 

erythropoietin substance with pectin at 0.05% and 0.005% concentrations. The levels of reticulocytes in these groups reached 

13.53% and 14.55%, respectively. The results of the myelogram during immunosuppression showed some activity of 

erythropoietin in conjunction with both concentrations of pectin when a two-fold increase in the number of erythroblasts was 

observed on the 5th day. High degrees of erythrokaryocytes in the state of mitosis were observed in the 0.05% pectin samples. 

Similar results were observed in equivalent groups of control animals on the 10th day of the experiment, which is compatible 

with the data on Eprex action. 

 

Conclusion: The erythropoietic activity of nano-encapsulated forms of erythropoietin was observed in the 0.05% and 0.005% 

pectin samples in the cyclophosphamide immunosuppression model setting. 

Keywords: erythropoiesis, nanobiotechnology, recombinant human erythropoietin 

 

http://www.library.pitt.edu/
http://www.pitt.edu/
http://www.library.pitt.edu/articles/digpubtype/index.html
http://www.upress.pitt.edu/upressIndex.aspx